Momelotinib
- Generic Name
- Momelotinib
- Brand Names
- Ojjaara, Omjjara
- Drug Type
- Small Molecule
- Chemical Formula
- C23H22N6O2
- CAS Number
- 1056634-68-4
- Unique Ingredient Identifier
- 6O01GMS00P
- Background
Momelotinib is a Janus Kinase 1 (JAK1) and 2 (JAK2) inhibitor. It is a competitive inhibitor of JAK ATP binding. First approved by the FDA on September 15, 2023, momelotinib is used to treat myelofibrosis. Myelofibrosis (MF) is a group of myeloproliferative neoplasms characterized by abnormal proliferative hematopoietic stem cells, leading to the release of ...
- Indication
Momelotinib is indicated for the treatment of intermediate or high-risk myelofibrosis (MF), including primary MF or secondary MF [postpolycythemia vera (PV) and post-essential thrombocythemia (ET)], in adults with anemia.
- Associated Conditions
- High risk Myelofibrosis, Intermediate risk Myelofibrosis
- Associated Therapies
- -
Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis
- First Posted Date
- 2013-10-25
- Last Posted Date
- 2023-05-12
- Lead Sponsor
- Sierra Oncology LLC - a GSK company
- Target Recruit Count
- 432
- Registration Number
- NCT01969838
Safety Study Evaluating Twice-Daily Administration of Momelotinib in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis
- Conditions
- Interventions
- First Posted Date
- 2011-08-25
- Last Posted Date
- 2019-02-04
- Lead Sponsor
- Sierra Oncology LLC - a GSK company
- Target Recruit Count
- 61
- Registration Number
- NCT01423058
- Locations
- 🇺🇸
Mayo Clinic, Jacksonville, Florida, United States
🇺🇸MD Anderson Cancer Center, The University of Texas, Houston, Texas, United States
🇨🇦Princess Margaret Hospital, Toronto, Ontario, Canada
Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)
- Conditions
- Interventions
- First Posted Date
- 2010-11-08
- Last Posted Date
- 2019-02-04
- Lead Sponsor
- Sierra Oncology LLC - a GSK company
- Target Recruit Count
- 120
- Registration Number
- NCT01236638
- Locations
- 🇨🇦
Jewish General Hospital, Montreal, Quebec, Canada
🇺🇸Stanford Cancer Center, Stanford, California, United States
🇨🇦Princess Margaret Hospital, Toronto, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.